{"i": ["certolizumab pegol", "placebo - controlled"], "o": ["participation in daily activities"]}
{"i": [], "o": []}
{"i": ["certolizumab pegol ( CZP )"], "o": []}
{"i": ["placebo - controlled"], "o": []}
{"i": ["placebo , CZP", "CZP"], "o": []}
{"i": ["PsA"], "o": ["paid work and household productivity", "participation in social activities", "- specific Work Productivity Survey ( WPS )"]}
{"i": [], "o": ["WPS responses"]}
{"i": ["placebo", "CZP"], "o": []}
{"i": ["placebo", "CZP"], "o": ["absenteeism and presenteeism"]}
{"i": ["placebo", "CZP"], "o": ["household work days"]}
{"i": ["CZP"], "o": ["reduced household productivity or days lost for participation in family , social and leisure activities ."]}
{"i": [], "o": ["CZP"]}
{"i": ["CZP"], "o": []}
{"i": [], "o": []}
{"i": ["certolizumab pegol ( CZP )"], "o": []}
{"i": ["placebo - controlled"], "o": []}
{"i": ["placebo , CZP", "CZP"], "o": []}
{"i": ["PsA"], "o": ["paid work and household productivity", "participation in social activities", "- specific Work Productivity Survey ( WPS )"]}
{"i": [], "o": ["WPS responses"]}
{"i": ["placebo", "CZP"], "o": []}
{"i": ["placebo", "CZP"], "o": ["absenteeism and presenteeism"]}
{"i": ["placebo", "CZP"], "o": ["household work days"]}
{"i": ["CZP"], "o": ["reduced household productivity or days lost for participation in family , social and leisure activities ."]}
{"i": [], "o": ["CZP"]}
{"i": ["CZP"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["loss of productivity", "quality of life", "work disability"]}
{"i": [], "o": []}
{"i": [], "o": ["employment rate"]}
{"i": [], "o": []}
{"i": ["placebo", "tumour necrosis factor ( TNF ) inhibitor"], "o": ["ability to fulfil personal roles , social life and work", "ability to work or volunteer16"]}
{"i": ["certolizumab pegol ( CZP ),", "CZP"], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["C - reactive protein levels", "erythrocyte sedimentation rate"]}
{"i": ["TNF inhibitor"], "o": []}
{"i": ["CZP"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["placebo - controlled"], "o": []}
{"i": ["placebo", "CZP"], "o": []}
{"i": ["CZP", "Placebo"], "o": ["tender and swollen joint counts"]}
{"i": [], "o": ["ACR20 response", "modified Total Sharp Score ( mTSS )"]}
{"i": ["CZP"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["paid work productivity"]}
{"i": [], "o": ["absenteeism", "level of interference of arthritis on work productivity", "presenteeism ( days with work productivity"]}
{"i": [], "o": []}
{"i": [], "o": ["number of days with no household work performed due to arthritis ; days with household productivity reduced by \u2265 50 % due to arthritis ; days with outside help hired due to arthritis ; days with family , social or leisure activities missed due to arthritis", "level of arthritis interference with household productivity"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["workplace productivity"]}
{"i": [], "o": ["productivity in the workplace"]}
{"i": ["placebo", "CZP"], "o": ["WPS responses"]}
{"i": ["placebo"], "o": []}
{"i": [], "o": ["WPS scores"]}
{"i": [], "o": ["Cumulative productivity scores"]}
{"i": ["placebo", "CZP"], "o": []}
{"i": [], "o": []}
{"i": ["placebo", "CZP"], "o": []}
{"i": ["placebo - controlled", "placebo", "CZP"], "o": []}
{"i": ["CZP"], "o": []}
{"i": ["CZP", "Placebo"], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": [], "o": ["PASI scores"]}
{"i": ["CS", "MTX"], "o": []}
{"i": ["certolizumab pegol", "methotrexate"], "o": ["BMI , body mass index ; BSA , body surface area ; CS", "; PASI , Psoriasis Area and Severity Index ; Q2W"]}
{"i": ["placebo , CZP", "CZP"], "o": []}
{"i": [], "o": ["unable to work"]}
{"i": [], "o": ["burden of disease"]}
{"i": ["PsA"], "o": ["workplace productivity"]}
{"i": ["Placebo CZP", "CZP"], "o": ["days missed", "Mean Median Productivity"]}
{"i": [], "o": []}
{"i": ["CZP , certolizumab pegol ; PsA ,"], "o": []}
{"i": [], "o": ["household productivity"]}
{"i": [], "o": ["productivity"]}
{"i": [], "o": []}
{"i": ["placebo", "CZP"], "o": ["workplace productivity"]}
{"i": ["placebo", "CZP"], "o": ["absenteeism", "monthly rate of PsA interference with work productivity", "rate of PsA interference", "productivity"]}
{"i": ["placebo", "CZP"], "o": ["absenteeism", "PsA interference with paid work productivity"]}
{"i": [], "o": []}
{"i": ["Placebo CZP", "Placebo"], "o": ["Productivity at the workplace"]}
{"i": [], "o": []}
{"i": ["CZP , certolizumab pegol ; LOCF"], "o": []}
{"i": ["placebo", "CZP"], "o": ["not report workplace absenteeism"]}
{"i": [], "o": ["level of PsA interference with paid work productivity .", "number of paid work days with reduced productivity"]}
{"i": ["placebo", "CZP"], "o": ["workplace productivity"]}
{"i": ["placebo", "CZP"], "o": ["loss of productivity", "participation in daily activities"]}
{"i": ["CZP"], "o": ["household work productivity"]}
{"i": ["placebo", "CZP"], "o": ["reduced household productivity", "no household productivity per month", "rate of PsA interference", "monthly rate of PsA interference with work productivity"]}
{"i": ["placebo", "CZP"], "o": ["PsA interference with productivity within the home", "PsA interference with work", "productivity", "no household work", "household productivity"]}
{"i": ["placebo", "CZP"], "o": ["participation in family , social and leisure activities"]}
{"i": ["placebo"], "o": ["number of CZP patients with no days lost of household work"]}
{"i": [], "o": ["number of days with reduced household work productivity", "level of PsA interference with household work productivity", "number of days missed of family , social and leisure activities ."]}
{"i": ["placebo", "CZP"], "o": ["gains in full days of household work"]}
{"i": ["placebo", "CZP"], "o": ["social , family or leisure activities", "productive household work"]}
{"i": ["PsA"], "o": []}
{"i": [], "o": ["work disability"]}
{"i": [], "o": ["employment rate"]}
{"i": [], "o": []}
{"i": ["CZP"], "o": []}
{"i": ["CZP"], "o": ["workplace and household productivity ."]}
{"i": [], "o": ["productivity at work and within the home"]}
{"i": ["placebo"], "o": ["absenteeism and presenteeism"]}
{"i": ["CZP"], "o": ["productivity within the home", "days of lost participation in family , social and leisure activities"]}
{"i": ["CZP"], "o": []}
{"i": [], "o": []}
{"i": ["CZP plus methotrexate ( MTX )"], "o": []}
{"i": ["etanercept , infliximab and golimumab", "placebo plus MTX"], "o": ["participation in social activities"]}
{"i": [], "o": []}
{"i": [], "o": []}
{"i": ["anti - TNFs"], "o": []}
{"i": [], "o": []}
{"i": ["CZP"], "o": []}
{"i": ["PsA"], "o": ["patient productivity"]}
{"i": ["CZP"], "o": ["paid work productivity , household productivity and participation in family , social and leisure activities"]}
{"i": [], "o": ["quality of life"]}
